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Continuous Treatment With All-Trans Retinoic Acid Causes a Progressive 
Reduction in Plasma Drug Concentrations: Implications for Relapse and 
Retinoid “Resistance” in Patients With Acute Promyelocytic Leukemia 
By Josephia Muindi, Stanley R.  Frankel, Wilson H. Miller Jr, Ann Jakubowski, David A. Scheinberg, Charles W. Young, 
Ethan Dmitrovsky, and Raymond P. Warrell Jr 
Although all-trans retinoic acid (RA) induces complete remis- 
sion in a high proportion of patients with acute promyelo- 
cytic  leukemia  (APL),  all  groups  have  described  clinical 
relapses despite continued RA  treatment.  This finding sug- 
gests that resistance to  the cytodifferentiating effects of the 
retinoid had been acquired. To investigate potential mecha- 
nisms of clinical resistance to  RA,  we serially evaluated the 
clinical pharmacology of the drug in APL  patients treated 
with this agent. Leukemic cells from patients relapsing from 
RA  treatment were  cultured  in the  presence of  RA  and 
examined for evidence of morphologic maturation. We also 
studied messenger RNA expression of the newly described 
gene product of the (15;17) translocation in APL,  PMLIRA 
receptor-a  (PMLIRAR-a). Serial  pharmacokinetic  studies 
showed that continuous daily RA treatment was associated 
with a marked decrease in  plasma drug concentrations at the 
time of  relapse compared with the initial day of therapy. 
ECENT STUDIES have shown that a high proportion  R  of patients with acute promyelocytic leukemia (APL) 
achieve complete remission after treatment with all-trans 
retinoic  acid  (RA).’  However,  the  duration  of  these 
remissions has generally been brief,  and all groups have 
reported relapse despite continuous RA  treatment.'^^ These 
results have suggested that resistance to the antileukemic 
effects of  FL4  was acquired  during drug therapy. Several 
mechanisms of  acquired retinoid resistance have now been 
characterized in cell lines. Putative mechanisms of  in vitro 
resistance have included new mutations in nuclear retinoid 
receptors4,’  or alterations in the absolute amount or binding 
affinity of cellular RA  binding proteins (CRAJ3P).637 
To investigate the mechanisms of  clinical retinoid resis- 
tance, we evaluated patients who received RA  as induction 
treatment for APL with serial pharmacokinetic studies on 
the first day of  treatment, at the time of  relapse, and again 
after a twofold RA dose  escalation.  Leukemic cells ob- 
tained from four patients who relapsed  during RA treat- 
ment were cultured in vitro with RA and were examined for 
morphologic evidence of  differentiation.  In two  relapsing 
patients, messenger RNA (mRNA) expression of the newly 
described fusion gene product of  the characteristic (1517) 
translocation  in  APL,  PMLiRA receptor-a (RAR-a):’” 
was also studied to explore whether further abnormalities 
had been induced  in this receptor  during RA treatment. 
Results from these studies suggest that clinical resistance to 
RA treatment in APL may result from an induced pharma- 
cologic depression  of  plasma drug concentrations, poten- 
tially to levels that are inadequate to sustain differentiation 
in vivo. 
MATERIALS AND METHODS 
Patients in  this  study were  undergoing 
remission induction treatment for APL with all-trans RA at a dose 
of 45  mglm21d as  recently  described?  Six  patients  maintained 
Clinical information. 
Doubling the RA  dose  in six  patients  failed  to reinduce 
response at the time of relapse and also failed to  signficantly 
augment plasma RA concentrations. However, leukemic cells 
obtained at the time of relapse from four patients retained in 
vitro sensitivity  to the differentiating activity  of  RA  (lo-’ 
molIL). No change was observed in the pattern of PMLI 
RAR-a expression assessed by Northern blot analysis at the 
time of relapse compared with pretreatment in two patients 
who were tested. These results indicate that clinical relapse 
and ”resistance”  to continuous treatment with all-trans RA 
in APL is associated with progressive reduction of plasma 
concentrations, potentially to  levels below  those that  sustain 
differentiation of leukemic cells in  vivo. Long-term success of 
this treatment will require the  development of strategies that 
circumvent this pharmacologic phenomenon. 
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solely on RA relapsed during treatment and had no further clinical 
response  despite an  increase  in  the  daily  dose  from  45  to  90 
mglm’id. 
On day 1 of  therapy, patients received 
a single oral RA dose of  45 mg/m2. Heparinized  blood  samples 
were obtained before drug administration and at 0.5, 1, 2, 3, 4, 6, 
and 24 hours. Urine was collected in three aliquots from 0 to 6,6  to 
12, and 12 to 24 hour intervals after drug ingestion. These assays 
were  repeated at the  time of  relapse  in  six patients  who were 
maintained on the drug after having achieved complete remission 
(CR). At that time, the pharmacokinetic study was performed on 
the final day of treatment with the dose used for maintenance (45 
Pharmacokinetic studies. 
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mgim’id)  and again shortly after the RA dose was doubled to 90 
mglm’id. 
Reagents  and  analytical  techniques.  All-trans-9-nosityl-3,7- 
dimethyl-2,4,6,8  nonatetraenoic acid (the internal standard), 4-OXO- 
13-cis RA, and 4-oxo-all-trans RA were kindly supplied by  Dr F. 
Vane  (Hoffmann-LaRoche,  Nutley,  NJ).  P-Glucuronidase  type 
VILA (from Escherichia coli), all-trans RA, and 13-cis RA were 
purchased  from  Sigma  Chemical  Co  (St  Louis,  MO).  Other 
chemicals were from either Baker Chemical Co (Phillipsburg, NJ) 
or Fisher Scientific (Fair Lawn, NJ) and were of HPLC or highest 
grade available. Because retinoids may degrade with exposure to 
light, samples were transported in amber-colored plastic bags and 
were processed under low-light conditions. 
Plasma  samples were  extracted and assayed by  HPLC as de- 
scribed by Bugge et al.” Retinoids were detected by UV absorption 
at 365 nm (attenuation = 0.01). Selected plasma samples that fell 
below the  sensitivity limits of  this HPLC technique (10 ng/mL) 
were assayed by  a recently described liquid chromatographyimass 
spectrometry  method.”  Standard curves for all-trans RA, 13-cis 
RA, and their  4-oxo metabolites were established  using pooled 
normal plasma and were linear over a range from 0 to 1,OOO  ng/mL. 
The plasma half-life was estimated using computerized  software 
(PCNONLIN84; Statistical Consultants, Inc, Lexington, KY), and 
the  area  under  the  concentration  x  time  curve  (AUC)  was 
determined by trapezoidal approximation. 
Heparinized  bone  marrow  aspirates 
were obtained from four patients at presentation and again at the 
time of  relapse from RA treatment. The low density fraction of 
bone  marrow  mononuclear  cells  obtained  after  Ficoll-Hypaque 
centrifugation  was  washed  twice  with  cold  RPMI  media  and 
suspended  in  liquid  cultures  with  media  containing  10%  heat- 
inactivated fetal calf serum and 1%  glutamine. The cell suspen- 
sions were cocultured with all-trans RA  moliL) (Hohann- 
LaRoche Inc) dissolved in 95% ethanol and grown in a 5%  CO, 
humidified incubator at 37°C. Cell cultures with or without  RA 
(controls) were maintained for 10 days; cell counts and cytospin 
preparation for morphology were performed every 2 days. Morpho- 
logic  evidence  of  maturation  on  Wright-Giemsa-stained  slides 
included  chromatin  condensation,  nuclear  segmentation,  de- 
creased cytoplasmic basophilia,  and changes in granular appear- 
ance. 
Bone marrow mononuclear 
cells from two patients were purified by Ficoll-Hypaque centrifuga- 
tion of heparinized marrow aspirates obtained immediately before 
RA treatment and at the time of  relapse from a RA-maintained 
remission. Northern blot  analysis for  both  normal  RAR-a and 
PMLIRAR-a was performed on total cellular RNA as previously 
described.” 
Leukemia  cell  cultures. 
Northem blot  analysis of RAR-0. 
RESULTS 
Ten patients were evaluated on day 1 
after treatment with a single oral RA dose of  45  mg/m2. 
Oral administration of  the first dose of  RA produced peak 
plasma concentrations within 1  to 2 hours after administra- 
tion. The calculated mean plasma AUC for a group of  10 
patients on day 1 was 499  & 200 ng  . h/mL. Six patients 
were studied at the time of relapse; the mean AUC of these 
patients was significantly lower compared with the group 
mean value on day 1  (244 2 145 ng .  h/mL; P < .03). These 
six  individuals then  received  90  mg/m2 orally; however, 
despite the twofold dose increase, their mean plasma AUC 
was not augmented (222 2 112 ng .  h/mL; P = .56) (Table 
1.). While  the preceding  data are comparisons of  group 
Pharmacokinetics. 
Table 1.  Changes in Pharmacokinetic  Parameters on Day 1 of 
Treatment Compared With the Time of Relapse After Continuous 
Daily Administration  of All-Trans RA 
Mean AUC (*SO)  N  Time  Dose (mg/m’) 
A.  Day 1  45  10  499 * 200 
B.  Relapse  45  6  244 k 145 
C.  Relapse  90  6  222 f  112 
A v B, P = .03;  B v C, P  = .56; paired t-test. 
mean values, three individual patients were studied at all 
three time points. Mean plasma RA concentrations versus 
time are depicted in Fig 1; these intrapatient data show a 
similar  pattern  of  plasma  level  reduction  and  lack  of 
increase with increased dosage. 
Of interest, we studied one patient who has remained in 
CR for the longest period in our study while maintained on 
continuous  RA treatment.  As shown in Fig 2, when this 
patient was studied while in CR at 8 months, her calculated 
plasma AUC was similar to her day 1  value (365 v 406 ng . 
h/mL). 
In vitro cellular differentiation.  Leukemic cells from four 
patients who relapsed from CR while maintained solely on 
RA were cultured in vitro with RA  mol/L). Compared 
with  controls,  morphologic  examination  of  RA-cultured 
cells showed changes consistent with  maturation  (ie, in- 
crease  in  nuclear  chromatin  condensation  and  partial 
nuclear segmentation), suggesting that leukemic cells from 
these clinically resistant patients retained in vitro sensitivity 
to the cytodifferentiating activity of RA. 
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Fig  1.  Plasma concentrations (kSEM) of  all-trans RA  after the 
administration  of a single oral dose (45 mg/m2)  on day 1 of treatment 
in three patients (O),  at the time of relapse (A), and at relapse (m) 
after treatment with a single dose of 90 mg/m2.  The calculated plasma 
AUC concentrations were significantly lower at the time of relapse 
compared with day  1 and were not increased despite the twofold 
escalation in dose. 
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We  had originally surmised  that  continuous RA treat- 
mcnt during CR after the lcukcmic cell burdcn had been 
reduced might cause a progressive increase in plasma drug 
concentrations, thcrcby increasing toxicity ovcr time. Unex- 
pectedly, wc  found that continuous treatment was associ- 
ated  with  progrcssivcly  diminishing  plasma  levels.  The 
onset of  this effect is relatively rapid and occurs within 2-6 
weeks from thc initiation of  trcatmcnt  in most patients." 
This effect  has  not becn  prcviously described  in  human 
subjects, and  it does not  occur during thcrapy with other 
retinoids such as 134s  RA or etretinate.'"."  However, our 
observations are consistent with reccnt data derived from 
other species. Creech Kraft et allh  described a reduction in 
plasma levels of all-trans RA in two Cynomolgus monkeys 
that underwent serial studies, and Kalin et all7  showed that 
RA pretreatment in mice rcduccd subsequent plasma AUC 
concentrations. Notably, treatment with  134  RA did not 
induce these effects in cithcr ~pccies.'~.'~ 
Several explanations  could  account  for the  pharmaco- 
logic behavior observed here. First, because biliary excre- 
tion  accounts  for  at  least  60%  of  RA  elimination  in 
rodents," it is conceivable that clinically unapparent malab- 
I  I  I  I  I  I  I  I 
12345678 
Hours 
Fig 2.  Plasma concentrations of all-trans RA  in the same patient 
after administration of  a single oral doses (45 mg/m2) on day 1 of 
treatment (0)  and after 8 months in CR  (A).  The calculated plasma 
AUC concentrations were not different in this individual during this 
extended  remission. 
Northern blot analysis of  PMLIRAR-a  Serial Northern 
blot  analysis of  total  cellular  RNA  from  bone  marrow 
mononuclear cells taken from two relapsing patients showed 
that  there  was  no  change  in  the  migration  of  mRNA 
transcripts of PMLIRAR-a or in normal RAR-a before RA 
treatment or after relapse. Gels from one of  these patients  -  28s 
"1 
+  A 
-w  RAR  -CY 
are illustrated  in  Fig  3.  In  these  patients,  an  identical 
pattern of  reverse transcriptaseIpolymerase chain reaction 
amplification  products  was  also  observed  using  specific 
primers for the fusion receptor molecule (Dr W.H. Miller 
Jr, unpublished data).  -  18s 
DISCUSSION 
Despite a high initial CR rate, unexplained relapses have 
occurred  in  many  patients  with  APL despite  continued 
treatment  with  all-trans RA.'"  This finding suggests that 
resistance to the cytodifferentiating actions of  thc retinoid 
had been acquired during the course of  therapy; however, 
the mechanisms that underlie such resistance have not been 
previously examined in the clinical setting. Prior studies in 
vitro have shown that retinoid resistancc can be induced by 
continuous culture in high concentrations of  RA, and that 
this  resistance  is  associated  with  acauired  mutations  in  Fig 3.  Northern blot analysis of total cellular mRNA obtained  from 
I 
12 
retinoic acid receptorSJ5 or with alterations  in the expres- 
that  resistance to  RA  therapy in APL may 
leukemic cells of one patient with acquired RA resistance. Arrows 
indicate two  abnormal  transcripts.  No  change  in  the  migration 
sewed in cells before RA treatment fleft lane)  or durina relame from a 
Of  However, data from  Our  study  indicate  patterns of aberrant pML/MR-a or  normal RAR-a mRNA was ob- 
- 
have a simpler pharmacologic explanation.  RA-induced remission (right lane). 
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sorption  or nonspecific binding to intestinal  proteins re- 
duced  the  oral  bioavailability.  However,  we  previously 
noted  that  urinary  excretion  of  the  4-oxo-all-pans  RA 
metabolite  increased  approximately 10-fold with continu- 
ous  daily  treatment  despite  a  decrease  in  peak  plasma 
 level^.'^ Although this amount accounts for less than 1%  of 
the  administered  dose  in  humans,  these  data  and  the 
absence of  any other evidence for malabsorption  suggest 
that an induced progressive impairment of  gastrointestinal 
uptake is unlikely. 
Second, continued RA treatment could result in further 
RAR-a mutations.  Such  mutations  have  been  observed 
after F9 teratocarcinoma cells were rendered resistant after 
long-term cultures with  high RA concentration in vitro.4 
However, we failed to detect changes in the migration of 
the  normal  or mutated RAR-a species in  either  of  our 
patients who were  examined by  Northern  analysis at re- 
lapse compared with presentation. We note that the concen- 
trations of  RA that are achieved in human plasma (Fig 1 
and Table 1; 300 p,g/mL = 1  kmol/L) are quite low relative 
to concentrations that have been used for continuous cell 
cultures in ~itro.~~’~~~  Resolution of  this issue will  depend 
upon sequence analysis of PML IRAR-a in larger numbers 
of  patients  now  in  progress, but  to date this explanation 
appears doubtful. 
A third possibility is that enzymes responsible for cata- 
bolic drug conversion are induced by continuous treatment. 
A cytochrome P450-like enzyme system catalyzes the oxida- 
tion of  RA that leads to the formation of  4-oxo-all-trans 
RA.  19.20  Phenobarbital,  a prototype  drug that  induces  its 
own catabolism by  induction of  the P450 system, markedly 
increases the plasma clearance of  both  all-trans RA and 
13-cis RA,” yet repeated treatment with 134  RA does not 
induce the pharmacokinetic behavior we  describe for all- 
trans  RA.  Phenobarbital-induced  accelerated  catabolism 
can  be  overcome  by  simply  increasing  the  drug  dose; 
however, a  twofold  dose  increase  of  RA in  six  of  our 
patients not only failed to recapture their clinical response, 
but also failed to significantly increase plasma drug concen- 
trations. 
Although  the  inability  to  present  an  effective  drug 
concentration to leukemic cells in plasma may be a primary 
mechanism for relapse from RA-induced  remissions, the 
low plasma concentrations do not necessarily imply pharma- 
cologic  inactivity in  other  tissues.  One  of  our  patients 
experienced  marked  drug-related  toxicity  (pseudotumor 
cerebri) during a period when her plasma concentrations 
were undetectable by  HPLC (R. Warrell Jr, unpublished 
observations).  Thus,  accelerated  enzymatic  degradation 
may  not  constitute the complete pharmacologic explana- 
tion for this phenomenon. An important additional factor 
may  be that RA increases  the expression of  CRABP in 
normal  body  tissues.  Several  studies  have  shown  that 
repeated  topical  application  of  all-trans  RA  increases 
CRABP in human skin.’*,= Epidermal CRABP levels were 
also  found  to  increase  after systemic administration  of 
acitretin but  not  after treatment  with  134s RA.24  One 
possible consequence of  a generalized increase in CRABP 
would be that normal tissues could act as a large “retinoid 
sink,”  resulting  in  accelerated  clearance  and  very  low 
plasma  concentrations  after continuous  therapy,  as  ob- 
served in this study. Increased CRABP within the leukemic 
cell  could  also  act  to  sequester  RA intracellularly  and 
prevent  its  transport  to the n~cleus~~~~*~;  however, other 
human myeloid leukemic cells (HL-60 and KG-I) selected 
for resistance to all-trans RA do not show an increase in 
CRABP  expression  (nor  does  it  appear  that  CRABP 
mediates RA-induced differentiation of these cells).*6  More- 
over, leukemic cells obtained from four of our patients who 
were clinically resistant retained in vitro sensitivity to the 
morphologic differentiating activity of  the drug. Similar to 
other studie~,~.~,~.’’  these experiments were conducted using 
a single, relatively high concentration of  RA  mol/L). 
Retinoid “resistance” is not likely an all-or-none phenome- 
non  and  more detailed  studies may  show  a  shift in  the 
concentration/response curve. 
If induced accelerated catabolism is the principal mecha- 
nism  that  underlies the progressive reduction  in  plasma 
concentrations, coadministration of  a P450 enzyme inhibi- 
t~?’,~  could ameliorate this problem. If increased CRABP 
expression in normal cells is primarily responsible, intermit- 
tent treatment  (eg, dosing on alternate weeks, alternate 
months, etc) might minimize the effect because downregu- 
lation of the protein may occur rapidly after removal of the 
stimulus. Alternatively, because  this effect has not  been 
reported for other retinoids, other compounds may need to 
be identified that share the exquisite therapeutic sensitivity 
for the disease but do not upregulate CRABP. Studies that 
evaluate  the time-course  of  CRABP expression  in  vivo 
during chronic RA treatment, as well as the use of  P450 
inhibitors, are currently  in  progress.*’ Strategies to over- 
come  these  pharmacologic  effects  are  clearly  desirable 
before initiating large-scale studies that use chronic dosing 
with all-trans RA in patients with APL and other cancers. 
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